• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Study: Experimental anorexia treatment with deep brain stimulation may provide lasting results

Study: Experimental anorexia treatment with deep brain stimulation may provide lasting results

March 7, 2013 By Arezu Sarvestani

deep brain stimulation illustration

In what some are calling "a world 1st," researchers reported some success in treating severe anorexia patients via implanted electrodes that delivered electrical energy to the regions of the brain associated with emotion.

The study enrolled 6 patients to receive the experimental treatment, reporting that 3 of the 6 achieved weight gain and 4 of the 6 reported changes in mood, anxiety, control over their urges to binge and purge and other symptoms associated with anorexia.

"There is an urgent need for additional therapies to help those suffering from severe anorexia," researcher Dr. Blake Woodside said in prepared remarks. "Eating disorders have the highest death rate of any mental illness and more and more women are dying from anorexia."

"Any treatment that could potentially change the natural course of this illness is not just offering hope but saving the lives for those that suffer from the extreme form of this condition," Woodside added.

The patient involved in the study were considered at high risk of chronic illness or premature death as a result of the severity of their anorexia. They had an average age of 38 and had suffered from anorexia for an average of 18 years. Each patient had previously suffered medical complications as a result of the anorexia and all but 1 also had psychiatric conditions, such as major depressive disorder and obsessive-compulsive disorder.

The patients were implanted with electrodes that were placed in regions of the brain determine to be highly important in disorders such as depression. The electrodes were connected to an electrical pulse generator that was implanted below the right clavicle, "much like a heart pacemaker," the researchers reported.

"After a 9-month period following surgery, the team observed that 3 of the 6 patients had achieved weight gain which was defined as a body-mass index (BMI) significantly greater than ever experienced by the patients. For these patients, this was the longest period of sustained weight gain since the onset of their illness," according to the report. "Furthermore, 4 of the 6 patients also experienced simultaneous changes in mood, anxiety, control over emotional responses, urges to binge and purge and other symptoms related to anorexia, such as obsessions and compulsions. As a result of these changes, 2 of these patients completed an inpatient eating disorders program for the 1st time in the course of their illness."

The findings may mark a shift in treatment for anorexia, as well as other mental disorders. Tech-based approaches to psychiatric issues are rare, although they do exist. Pennsylvania medical device maker Neuronetics in 2008 was the 1st to win FDA clearance to market a DBS-based depression therapy, namely its NeuroStar TMS non-invasive electromagnetic field treatment.

St. Jude Medical‘s (NYSE:STJ) is also examining deep brain stimulation as a platform for treating mental health issues such as depression. and Jerusalem-based Brainsway Ltd. (PINK:BRSYF) has had Israeli regulatory approval since October 2011 for its transcranial magnetic stimulation device to treat major depression, bipolar disorder and negative impairment in schizophrenia patients.

Filed Under: Neuromodulation/Neurostimulation, News Well, Research & Development, Weight loss Tagged With: Brainsway, Clinical Trials, Neuronetics, Psychiatry, stjudemedical

In case you missed it

  • 3M Health Care Business president is leaving this year
  • Device developer SeaStar Medical hires chief medical officer
  • AccuPulse raises $10M Series A
  • Exactech announces first U.S. surgeries with its nex-gen laser cage glenoid
  • Baxter expects sales growth momentum through 2025
  • Vivera picks up new patent for electronic dose-controlled drug delivery devices
  • Stryker launches dynamic compression system for foot, ankle applications
  • Entegris opens Life Sciences Technology Center in Massachusetts
  • Glucose monitor maker Know Labs expands leadership team
  • inHeart wins FDA clearance for 3D cardiac modeling software
  • How Glytec is advancing insulin management in the hospital
  • Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
  • FDA clears RapidAI’s pulmonary embolism triage platform
  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive

RSS From Medical Design & Outsourcing

  • 3M Health Care Business president is leaving this year
    3M Health Care Business Group President Mojdeh Poul will retire from the company on July 1, 2022. Poul joined Maple Grove, Minnesota-based 3M (NYSE:MMM) in 2011 as the global business VP of critical and chronic care solutions. She later became VP and general manager of the company’s food safety business and president of numerous 3M… […]
  • Iterative Scopes announces positive data in Skout AI colonoscopy algorithm clinical trial
    Iterative Scopes this week announced positive trial data in a study of its colorectal cancer screening algorithm, Skout. Cambridge, Massachusetts-based Iterative Scopes designed Skout as a computer-aided device (CADe) that uses artificial intelligence and computer vision technology to detect suspicious tissue and provide real-time feedback for gastroenterologists performing the procedure. Get the full story on… […]
  • Device developer SeaStar Medical hires chief medical officer
    SeaStar Medical has hired Dr. Kevin Chung as chief medical officer of the medtech developer starting July 1. Denver-based SeaStar is developing a platform therapy focused on hyperinflammation of vital organs. The company’s Selective Cytopheretic Device was designated as a breakthrough device by the FDA earlier this year. SeaStar is set to go public in… […]
  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]
  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS